Detalhe da pesquisa
1.
Expanding the Staging Criteria for T1-2N0 Hormone-Receptor Positive Breast Cancer Patients Enrolled in TAILORx.
Ann Surg Oncol
; 29(13): 8016-8023, 2022 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-35900648
2.
Response to neoadjuvant chemotherapy and the 21-gene Breast Recurrence Score test in young women with estrogen receptor-positive early breast cancer.
Breast Cancer Res Treat
; 186(1): 157-165, 2021 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-33150547
3.
Discordance in Oncotype DX Breast Recurrence Score® Results for Bilateral Breast Cancer.
Ann Surg Oncol
; 28(13): 8711-8716, 2021 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-34241750
4.
Factors associated with MRI detection of occult lesions in newly diagnosed breast cancers.
J Surg Oncol
; 121(4): 589-598, 2020 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-31984517
5.
ASO Visual Abstract: Expanding Staging Criteria in T1-2N0 Hormone Receptor-Positive Breast Cancer Patients Enrolled in TAILORx.
Ann Surg Oncol
; 29(13): 8024-8025, 2022 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-35902504
6.
Value of routine staging imaging studies for patients with stage III breast cancer.
J Surg Oncol
; 114(8): 917-921, 2016 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-27642105
7.
Lymph node status in inflammatory breast cancer.
Breast Cancer Res Treat
; 151(1): 113-20, 2015 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-25846421
8.
Cost-Effectiveness Analysis of the Oncotype DX Breast Recurrence Score® Test from a US Societal Perspective.
Clinicoecon Outcomes Res
; 16: 471-482, 2024.
Artigo
em Inglês
| MEDLINE | ID: mdl-38855430
9.
Ductal carcinoma in situ (DCIS) of the breast: perspectives on biology and controversies in current management.
J Surg Oncol
; 105(2): 212-20, 2012 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-21751217
10.
Expanding Criteria for Prognostic Stage IA in Hormone Receptor-Positive Breast Cancer.
J Natl Cancer Inst
; 113(12): 1744-1750, 2021 11 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-34010423
11.
Neoadjuvant therapy for breast cancer.
J Surg Oncol
; 101(4): 283-91, 2010 Mar 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-20187061
12.
Young-Onset Colon Cancer and Recurrence Risk by Gene Expression.
J Natl Cancer Inst
; 112(11): 1170-1173, 2020 11 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32040172
13.
Molecular profiling for DCIS.
Clin Adv Hematol Oncol
; 12(9): 611-3, 2014 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-25654484
14.
Clinical relevance of the 21-gene Recurrence Score® assay in treatment decisions for patients with node-positive breast cancer in the genomic era.
NPJ Breast Cancer
; 4: 27, 2018.
Artigo
em Inglês
| MEDLINE | ID: mdl-30155517
15.
The tipping point: Tamoxifen toxicity, central serous chorioretinopathy, and the role of estrogen and its receptors.
Am J Ophthalmol Case Rep
; 3: 8-13, 2016 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-29503899
16.
Double-Blind Phase III Randomized Trial of the Antiprogestin Agent Mifepristone in the Treatment of Unresectable Meningioma: SWOG S9005.
J Clin Oncol
; 33(34): 4093-8, 2015 Dec 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-26527781
17.
Gemcitabine and platinum-based chemotherapy in metastatic breast cancer.
Oncology (Williston Park)
; 18(14 Suppl 12): 17-22, 2004 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-15685821
18.
Personalized medicine for breast cancer: it is a new day!
Am J Surg
; 207(3): 321-5, 2014 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-24581758
19.
Letrozole as adjuvant therapy for postmenopausal women with early breast cancer.
Manag Care Interface
; 20(9): 30-1, 36, 2007 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-18161388
20.
Phase III comparison of standard doxorubicin and cyclophosphamide versus weekly doxorubicin and daily oral cyclophosphamide plus granulocyte colony-stimulating factor as neoadjuvant therapy for inflammatory and locally advanced breast cancer: SWOG 0012.
J Clin Oncol
; 29(8): 1014-21, 2011 Mar 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-21220618